Literature DB >> 25647696

Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.

Marta Pardo1, Laura López-Cruz1, Noemí San Miguel1, John D Salamone2, Mercè Correa3,4.   

Abstract

RATIONALE: Low doses of dopamine (DA) antagonists and accumbens DA depletions reduce food-reinforced instrumental behavior but do not impair primary food motivation, causing animals to reallocate behavior away from food-reinforced tasks with high response requirements and select less effortful alternatives. However, it is uncertain if this same pattern of effects would occur if sucrose was used as the reinforcer.
OBJECTIVES: These experiments studied the impact of DA depletion and antagonism on performance of an effort-related choice task using sucrose as the reinforcer, as well as sucrose consumption, preference, and taste reactivity tests.
METHODS: The effects of DA manipulations were assessed using a task in which rats chose between lever pressing on a fixed ratio 7 schedule for 5.0 % sucrose versus freely consuming a less concentrated solution (0.3 %).
RESULTS: The DA depleting agent tetrabenazine shifted effort-related choice, decreasing lever pressing for 5.0 % sucrose but increasing intake of the concurrently available 0.3 % sucrose. Tetrabenazine did not affect sucrose appetitive taste reactivity, or sucrose consumption or preference, in free consumption tests. The D1 antagonist ecopipam and the D2 antagonist haloperidol also shifted choice behavior at doses that did not alter sucrose consumption or preference. In contrast, sucrose pre-exposure reduced consumption across all conditions. D3 antagonism had no effects.
CONCLUSIONS: D1 and D2 receptor blockade and DA depletion reduce the tendency to work for sucrose under conditions that leave fundamental aspects of sucrose motivation (intake, preference, hedonic reactivity) intact. These findings have implications for studies employing sucrose intake or preference in animal models of depression.

Entities:  

Keywords:  Anergia; Anhedonia; Decision making; Depression; Dopamine; Motivation

Mesh:

Substances:

Year:  2015        PMID: 25647696     DOI: 10.1007/s00213-015-3872-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  86 in total

1.  Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.

Authors:  J S Schneider; A Pope; K Simpson; J Taggart; M G Smith; L DiStefano
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

Review 2.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 3.  The mysterious motivational functions of mesolimbic dopamine.

Authors:  John D Salamone; Mercè Correa
Journal:  Neuron       Date:  2012-11-08       Impact factor: 17.173

4.  Sensitization of midbrain dopamine neuron reactivity promotes the pursuit of amphetamine.

Authors:  Paul Vezina; Daniel S Lorrain; Gretchen M Arnold; Jennifer D Austin; Nobuyoshi Suto
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

Review 5.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

6.  Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs.

Authors:  M S Cousins; W Wei; J D Salamone
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

7.  Ventrolateral striatal dopamine depletions impair feeding and food handling in rats.

Authors:  J D Salamone; K Mahan; S Rogers
Journal:  Pharmacol Biochem Behav       Date:  1993-03       Impact factor: 3.533

8.  The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure.

Authors:  Allison M Mott; Eric J Nunes; Lyndsey E Collins; Russell G Port; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2009-01-09       Impact factor: 4.530

9.  Negative symptoms of schizophrenia are associated with abnormal effort-cost computations.

Authors:  James M Gold; Gregory P Strauss; James A Waltz; Benjamin M Robinson; Jamie K Brown; Michael J Frank
Journal:  Biol Psychiatry       Date:  2013-02-07       Impact factor: 13.382

10.  Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia.

Authors:  Ryan D Ward; Eleanor H Simpson; Vanessa L Richards; Gita Deo; Kathleen Taylor; John I Glendinning; Eric R Kandel; Peter D Balsam
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

View more
  23 in total

1.  Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.

Authors:  Samantha E Yohn; Samantha L Collins; Hector M Contreras-Mora; Emily L Errante; Margaret A Rowland; Merce Correa; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

2.  Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.

Authors:  Samantha E Yohn; Laura Lopez-Cruz; Peter H Hutson; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2015-12-23       Impact factor: 4.530

3.  Mir363-3p attenuates post-stroke depressive-like behaviors in middle-aged female rats.

Authors:  Aditya Panta; Sivani Pandey; Irma N Duncan; Shaelynn Duhamel; Farida Sohrabji
Journal:  Brain Behav Immun       Date:  2019-01-10       Impact factor: 7.217

Review 4.  Role of Mesolimbic Brain-Derived Neurotrophic Factor in Depression.

Authors:  Ja Wook Koo; Dipesh Chaudhury; Ming-Hu Han; Eric J Nestler
Journal:  Biol Psychiatry       Date:  2019-06-04       Impact factor: 13.382

5.  Pharmacological studies of effort-related decision making using mouse touchscreen procedures: effects of dopamine antagonism do not resemble reinforcer devaluation by removal of food restriction.

Authors:  Jen-Hau Yang; Rose E Presby; Adam A Jarvie; Renee A Rotolo; R Holly Fitch; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2019-08-08       Impact factor: 4.530

Review 6.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

Review 7.  Stress effects on the neural substrates of motivated behavior.

Authors:  Nick G Hollon; Lauren M Burgeno; Paul E M Phillips
Journal:  Nat Neurosci       Date:  2015-09-25       Impact factor: 24.884

8.  Dissociating the effects of dopamine D2 receptors on effort-based versus value-based decision making using a novel behavioral approach.

Authors:  Matthew R Bailey; Eileen Chun; Elke Schipani; Peter D Balsam; Eleanor H Simpson
Journal:  Behav Neurosci       Date:  2020-04       Impact factor: 1.912

9.  Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.

Authors:  Renee A Rotolo; Predrag Kalaba; Vladimir Dragacevic; Rose E Presby; Julia Neri; Emily Robertson; Jen-Hau Yang; Merce Correa; Vasiliy Bakulev; Natalia N Volkova; Christian Pifl; Gert Lubec; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2020-08-07       Impact factor: 4.530

Review 10.  The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation.

Authors:  John D Salamone; Mercè Correa; Sarah Ferrigno; Jen-Hau Yang; Renee A Rotolo; Rose E Presby
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.